Epstein-Barr virus-associated lymphoproliferative disorders

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 481-490

  Grywalska, Ewelina ^a   Markowicz, Justyna ^a   Grabarczyk, Piotr ^b   Pasiarski, Marcin ^c   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c HollyCross Cancer Center   (Poland)

Author keywords

EBV; Lymphoma; Lymphoproliferative disorder; Oncogenesis; Tumor

Indexed keywords

B LYMPHOCYTE; BURKITT LYMPHOMA; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HODGKIN DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; NONHODGKIN LYMPHOMA; REVIEW; VIROLOGY;

B-LYMPHOCYTES; BURKITT LYMPHOMA; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS;

EID: 84883877478     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1050999     Document Type: Article

References (119)

1. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G. W., Mautner J.: Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med., 2006;203:995-1006
2. Alexander F. E., Jarrett R. F., Lawrence D., Armstrong A. A., Freeland J., Gokhale D. A., Kane E., Taylor G. M., Wright D. H., Cartwright R. A.: Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br. J. Cancer, 2000;82:1117-1121
3. Allday M. J.: How does Epstein-Barr virus (EBV) complement the activation of myc in the pathogenesis of Burkitt's lymphoma? Semin. Cancer. Biol., 2009;19:366-376
4. Allen U., Alfieri C., Preiksaitis J., Humar A., Moore D., Tapiero B., Tellier R., Green M., Davies D., Hébert D., Weitzman S., Petric M., Jacobson K.: Canadian PTLD Workshop Group - 1999. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can. J. Infect. Dis., 2002;13:89-99
5. Arbach H., Viglasky V., Lefeu F., Guinebretière J. M., Ramirez V., Bride N., Boualaga N., Bauchet T., Peyrat J. P., Mathieu M. C., Mourah S., Podgorniak M. P., Seignerin J. M., Takada K., Joab I.: Epstein-Barr Virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J. Virol., 2006;80:845-853
6. Aydin G. B., Akyuz C., Talim B., Evans S. E., Sahin S., Sari N., Tabanlioglu D., Ozen S., Caglar M., Büyükpamukçu M.: Extranodal type T/NK-cell lymphoma with an atypical clinical presentation. Pediatr. Hematol. Oncol., 2007;24:291-299
7. Barin F.: Viruses and unconventional transmissible agents: update on transmission via blood. Transfus. Clin. Biol., 2000;7:5s-10s
8. Bevan M. J.: Helping the CD8+ T cell response. Nat. Rev. Immunol., 2004;4:595-602
9. Bocian J., Januszkiewicz-Lewandowska D.: Zakażenia EBV - cykl życiowy, metody diagnostyki, chorobotwórczość. Postȩpy Hig. Med. Dośw., 2011;65:286-298
10. Borza C. M., Hutt-Fletcher L. M.: Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat. Med., 2002;8:594-599
11. Boshoff C., Weiss R.: AIDS-related malignancies. Nat. Rev. Cancer, 2002;2:373-382
12. Bouffet E., Frappaz D., Pinkerton R., Favrot M., Philip T.: Burkitt's lymphoma: a model for clinical oncology. Eur. J. Cancer, 1991;27:504-509
13. Brady G., MacArthur G. J., Farrell P. J.: Epstein-Barr virus and Burkitt lymphoma. Postgrad. Med. J., 2008;84:372-377
14. Bräuninger A., Spieker T., Willenbrock K., Gaulard P., Wacker H. H., Rajewsky K., Hansmann M. L., Küppers R.: Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) Epstein-Barr virus-infected b cells in angioimmunoblastic t cell lymphoma. J. Exp. Med., 2001;194:927-940
15. Brink A. A., Dukers D. F., van den Brule A. J., Oudejans J. J., Middeldorp J. M., Meijer C. J., Jiwa M.: Presence of Epstein-Barr virus latency type III at the single cell level in posttransplantation lymphoproliferative disorders and AIDS related lymphomas. J. Clin. Pathol., 1997;50:911-918
16. Cann A. J.: Pathogenesis. In: Principles of Molecular Virology, 4th Edition, eds.: Cann A. J., Elsevier Inc, 2005, 238
17. Capello D., Rasi S., Oreste P., Veronese S., Cerri M., Ravelli E., Rossi D., Minola E., Colosimo A., Gambacorta M., Muti G., Morra E., Gaidano G.: Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. J. Pathol., 2009;218:478-486
18. Capello D., Rossi D., Gaidano G.: Post-transplant lymphoproliferativedisorders: molecular basis of disease histogenesis and pathogenesis. Hematol. Oncol., 2005;23:61-67
19. Carbone A., Gloghini A., Dotti G.: EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist, 2008;13:577-585
20. Carbone A., Gloghini A., Larocca L. M., Antinori A., Falini B., Tirelli U., Dalla-Favera R., Gaidano G.: Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood, 1999;93:2319-2326
21. Cartwright R. A., Watkins G.: Epidemiology of Hodgkin's disease: a review. Hematol. Oncol., 2004;22:11-26
22. Cesarman E., Mesri E. A.: Virus associated lymphomas. Curr. Opin. Oncol., 1999;11:322-332
23. Chan K. H., Ng M. H., Seto W. H., Peiris J. S.: Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV infection. J. Clin. Microbiol., 2001;39:4152-4154
24. Chapman A. L., Rickinson A.: Epstein-Barr virus in Hodgkin's disease. Ann. Oncol., 1998;9:S5-S16
25. Chen M. R.: Epstein-Barr virus, the immune system, and associated diseases. Front Microbiol. 2011;2:5
26. Cohen J. I., Bollard C. M., Khanna R., Pittaluga S.: Current understanding of the role of Epstein-Barr virus (EBV) in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk. Lymphoma, 2008;49:27-34
27. de Leval L., Hasserjian R. P.: Diffuse large B cell lymphomas and burkitt lymphoma. Hematol. Oncol. Clin. North Am., 2009;23:791-827
28. Deacon E. M., Pallesen G., Niedobitek G., Crocker J., Brooks L., Rickinson A. B., Young L. S.: Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med., 1993;177:339-349
29. Dirmeier U., Neuhierl B., Kilger E., Reisbach G., Sandberg M. L., Hammerschmidt W.: Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res., 2003;63:2982-2989
30. Dorsett Y., Robbiani D. F., Jankovic M., Reina-San-Martin B., Eisenreich T. R., Nussenzweig M. C.: A role for AID in chromosome translocations between c-myc and the IgH variable region. J. Exp. Med., 2007;204:2225-2232
31. Eligio P., Delia R., Valeria G.: EBV chronic infections. Mediterr. J. Hematol. Infect. Dis., 2010;2:e2010022
32. Epstein M. A., Achong B. G., Barr Y. M.: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1964;1:702-703
33. Farrell K., Jarrett R. F.: The molecular pathogenesis of Hodgkin lymphoma. Histopathology, 2011;58:15-25
34. Filipovich A. H., Mathur A., Kamat D., Shapiro R. S.: Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res., 1992;52:5465s-5467s
35. Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. L., Biro P. A., Fearon D. T.: Epstein-Barr virus receptor of human B-lymphocytes in the C3d receptor CR2. Proc. Natl. Acad. Sci. USA, 1984;81:4510-4514
36. God J. M., Haque A.: Burkitt lymphoma: pathogenesis and immune evasion. J. Oncol., 2010;2010:516047
37. Gratama J. W., Ernberg I.: Molecular epidemiology of Epstein-Barr virus infection. Adv. Cancer Res., 1995;67:197-255
38. Harris N. L., Jaffe E. S., Diebold J., Flandrin G., Muller-Hermelink H. K., Vardiman J., Lister T. A., Bloomfield C. D.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol., 1999;10:1419-1432
39. Herbst H., Foss H. D., Samol J., Araujo I., Klotzbach H., Krause H., Agathanggelou A., Niedobitek G., Stein H.: Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood, 1996;87:2918-2929
40. Higgins C. D., Swerdlow A. J., Macsween K. F., Harrison N., Williams H., McAulay K., Thomas R., Reid S., Conacher M., Britton K., Crawford D. H.: A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J. Infect. Dis., 2007;195:474-482
41. Hislop A. D., Taylor G. S., Sauce D., Rickinson A. B.: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol., 2007;25:587-617
42. Hjalgrim H., Friborg J., Melbye M.: The epidemiology of EBV and its association with malignant disease. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, eds., A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, K. Yamanishi. Cambridge University Press 2007, 929-959
43. Hodgkin lymphoma. In: WHO Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, vol. 3, eds.: S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, S. Harald, J. Thiele, J. W. Vardiman. IARC Press, Lyon 2008, 321-334
44. Honjo T., Kinoshita K., Muramatsu M.: Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu. Rev. Immunol., 2002;20:165-196
45. Hsu S. M., Lin J., Xie S. S., Hsu P. L., Rich S.: Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum. Pathol., 1993;24:249-255
46. Iannitto E., Ferreri A. J., Minardi V., Tripodo C., Kreipe H. H.: Angioimmunoblastic T cell lymphoma. Crit. Rev. Oncol. Hematol., 2008;68:264-271
47. IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 70: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/herpesvirus. World Health Organization, International Agency for Research on Cancer. IARC Press, Lyon 1997
48. Jaccard A., Hermine O.: Extranodal natural killer/T cell lymphoma: advances in the management. Curr. Opin. Oncol., 2011;23:429-435
49. Jaffe E. S., Chan J. K., Su IJ, Frizzera G., Mori S., Feller A. C., Ho F. C.: Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Am. J. Surg. Pathol., 1996;20:103-111
50. Jaffe E. S., Ralfkiaer E.: Angioimmunoblastic T-cell lymphoma. In:. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues, eds.: E. S. Jaffe, N. L. Harris, H. Stein, J. W. Vardiman. IRAC Press, Lyon 2001, 225-226
51. Jarrett A. F., Armstrong A. A., Alexander E.: Epidemiology of EBV and Hodgkin's lymphoma. Ann. Oncol., 1996;7:5-10
52. Jones J. F., Shurin S., Abramowsky C., Tubbs R. R., Sciotto C. G., Wahl R., Sands J., Gottman D., Katz B. Z., Sklar J.: T cell lymphomas containing Epstein-Barr virus DNA in patients with chronic Epstein-Barr virus infection. N. Engl. J. Med., 1988;318:733-741
53. Joo E. J., Ha Y. E., Jung D. S., Cheong H. S., Wi Y. M., Song J. H., Peck K. R.: An adult case of chronic active Epstein-Barr virus infection with interstitial pneumonitis. Korean J. Intern. Med., 2011;26:466-469
54. Kamranvar S. A., Gruhne B., Szeles A., Masucci M. G.: Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma. Oncogene, 2007;26:5115-5123
55. Kanegane H., Bhatia K., Gutierrez M., Kaneda H., Wada T., Yachie A., Seki H., Arai T., Kagimoto S., Okazaki M., Oh-ishi T., Moghaddam A., Wang F., Tosato G.: A syndrome of peripheral blood T cell infection with Epstein Barr virus (EBV) followed by EBV-positive T cell lymphoma. Blood, 1998;91:2085-2091
56. Kanegane H., Nomura K., Miyawaki T., Tosato G.: Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit. Rev. Oncol. Hematol., 2002;44:239-249
57. Kapatai G., Murray P.: Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J. Clin. Pathol., 2007;60:1342-1349
58. Kapp U., Yeh W. C., Patterson B., Elia A. J., Kägi D., Ho A., Hessel A., Tipsword M., Williams A., Mirtsos C., Itie A., Moyle M., Mak TW.: Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med., 1999;189:1939-1946
59. Kawa-Ha K., Ishihara S., Ninomiya T., Yumura-Yagi K., Hara J., Murayama F., Tawa A., Hirai K.: CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstei-Barr viral DNA. J. Clin. Invest., 1989;84:51-55
60. Kelly G. L., Milner A. E., Baldwin G. S., Bell A. I., Rickinson A. B.: Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA, 2006;103:14935-14940
61. Khan G., Miyashita E. M., Yang B., Babcock G. J., Thorley-Lawson D. A.: Is EBV persistence in vivo a model for B cell homeostasis? Immunity, 1996;5:173-179
62. Kitagawa N., Goto M., Kurozumi K., Maruo S., Fukayama M., Naoe T., Yasukawa M., Hino K., Suzuki T., Todo S., Takada K.: Epstein-Barr virus-encoded poly (A) (-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J., 2000;19:6742-6750
63. Knowles D. M.: The molecular genetics of post-transplantation lymphoproliferative disorders. Springer Semin. Immunopathol., 1998;20:357-373
64. Knowles D.: Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol. Oncol. Clin. N. Am., 2003;17:785-820
65. Küppers R.: B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol., 2003;3:801-812
66. Kulwichit W., Edwards R. H., Davenport E. M., Baskar J. F., Godfrey V., Raab-Traub N.: Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA, 1998;95:11963-11968
67. Kutok J. L., Wang F.: Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol., 2006;1:375-404
68. Levine A. M.: Acquired immunodeficiency syndrome-related lymphoma. Blood, 1992;80:8-20
69. Loren A. W., Porter D. L., Stadtmauer E. A., Tsai D. E.: Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant., 2003;31:145-155
70. MacMahon E. M., Glass J. D., Hayward S. D., Mann R. B., Charache P., McArthur J. C., Ambinder R. F.: Association of Epstein-Barr virus with primary central nervous system lymphoma in AIDS. AIDS Res. Hum. Retroviruses, 1992;8:740-742
71. Mueller N., Evans A., Harris N. L., Comstock G. W., Jellum E., Magnus K., Orentreich N., Polk B. F., Vogelman J.: Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N. Engl. J. Med., 1989;320:689-695
72. Münz C., Moormann A.: Immune escape by Epstein Barr virus associated malignancies, Semin. Cancer Biol., 2008;18:381-387
73. Murray P. G., Young L. S.: The role of the Epstein-Barr virus in human disease. Front Biosci., 2002;7:d519-d540
74. Mutalima N., Molyneux E., Jaffe H., Kamiza S., Borgstein E., Mkandawire N., Liomba G., Batumba M., Lagos D., Gratrix F., Boshoff C., Casabonne D., Carpenter L. M., Newton R.: Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One, 2008;3:e2505
75. Nador R. G., Cesarman E., Chadburn A., Dawson D. B., Ansari M. Q., Sald J., Knowles D. M.: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpesvirus. Blood, 1996;88:645-656
76. Nikiforow S., Bottomly K., Miller G., Münz C.: Cytolytic CD4+-T cell clones reactive to EBNA-1 inhibit Epstein-Barr virus-induced B cell proliferation. J. Virol., 2003;77:12088-12104
77. Nilsson K.: Human B-lymphoid cell lines. Hum. Cell, 1992;5:25-41
78. Ong K. W., Teo M., Lee V., Ong D., Lee A., Tan C. S., Vathsala A., Toh H. C.: Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin. Cancer Res., 2009;15:5350-5358
79. Parker A., Bowles K., Bradley J. A., Emery V., Featherstone C., Gupte G., Marcus R., Parameshwar J., Ramsay A., Newstead C.: Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS guidelines. Br. J. Haematol., 2010;149;675-692
80. Pasqualucci L., Bhagat G., Jankovic M., Compagno M., Smith P., Muramatsu M., Honjo T., Morse H. C., Nussenzweig M. C., Dalla-Favera R.: AID is required for germinal center-derived lymphomagenesis. Nat. Genet., 2008;40:108-112
81. Pietersma F., Piriou E., van Baarle D.: Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk. Lymphoma, 2008;49:1028-1041
82. Quintanilla-Martinez L., Kumar S., Fend F., Reyes E., Teruya-Feldstein J., Kingma D. W., Sorbara L., Raffeld M., Straus S. E., Jaffe E. S.: Fulminat EBV (+) T cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood, 2000;96:443-451
83. Raab-Traub N.: EBV-induced oncogenesis. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, eds.: A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, K. Yamanishi. Cambridge University Press, Cambridge 2007, 986-1006
84. Raphael M., Borisch B., Jaffe E.: Lymphomas associated with infection by the human immune deficiency virus (HIV). In: World Health Organization classification of tumors, pathology and genetics of tumors of haematopoietic and lymphoid tissues, eds. L Jaffe E., Harris N., Stein H., Vardiman J. IARC Press, Lyon, 2001, 260-263
85. Re D., Küppers R., Diehl V.: Molecular pathogenesis of Hodgkin's lymphoma. J. Clin. Oncol., 2005;23:6379-6386
86. Rezk S. A., Weiss L. M.: Epstein-Barr virus-associated lymphoproliferative disorders. Hum. Pathol., 2007;38:1293-1304
87. Riddler S. A., Breinig M. C., McKnight J. L.: Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood, 1994;84:972-984
88. Rizvi M. A., Evens A. M., Tallman M. S., Nelson B. P., Rosen S. T.: T cell non-Hodgkin's lymphoma. Blood, 2006;107:1255-1264
89. Said J. W.: Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv. Anat. Pathol.; 2007;14:189-194
90. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., Kieff E.: Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol., 1990;64:4084-4092
91. Sbih-Lammali F., Djennaoui D., Belaoui H., Bouguermouh A., Decaussin G., Ooka T.: Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. J. Med. Virol., 1996;49:7-14
92. Simonelli C., Spina M., Cinelli R., Talamini R., Tedeschi R., Gloghini A., Vaccher E., Carbone A., Tirelli U.: Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J. Clin. Oncol., 2003;21:3948-3954
93. Sixbey J. W., Nedrud J. G., Raab-Traub N., Hanes R. A., Pagano J. S.: Epstein-Barr virus replication in oropharyngeal epithelial cells. N. Engl. J. Med., 1984;310:1225-1230
94. Sixbey J. W., Shirley P., Chesney P. J., Buntin D. M., Resnick L.: Detection of a second widespread strain of Epstein-Barr virus. Lancet, 1989;2:761-765
95. Spina M., Tirelli U., Zagonel V., Gloghini A., Volpe R., Babare R., Abbruzzese L., Talamini R., Vaccher E., Carbone A.: Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer, 1998;82:766-774
96. Swinnen L. J.: Posttransplant lymphoproliferative disorders. In: Infectious causes of cancer: Targets for intervention, eds.: J. J. Goedert. Humana Press, Totowa 2000, 63-76
97. Szmidt A., Stańczyk-Przyłuska A.: Rola wirusa EBV w patogenezie chorób alergicznych. Alerg. Astma Immunol., 2005;10:169-174
98. Taylor A.. L, Marcus R., Bradley J. A.: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit. Rev. Oncol. Hematol., 2005;56:155-167
99. Thompson M. P., Kurzrock R.: Epstein-Barr virus and cancer. Clin. Cancer Res., 2004;10:803-821
100. Thompson S., Messick T., Schultz D. C., Reichman M., Lieberman P. M.: Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1. J. Biomol. Screen., 2010;15:1107-1115
101. Thorley-Lawson D. A.: Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol., 2001;1:75-82
102. Timms J. M., Bell A., Flavell J. R., Murray P. G., Rickinson A. B., Traverse-Glehen A., Berger F., Delecluse H. J.: Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet, 2003;361:217-223
103. Toczyski D. P., Matera A. G., Ward D. C., Steitz J. A.: The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes. Proc. Natl. Acad. Sci. USA, 1994;91:3463-3467
104. Trottier H., Buteau C., Robitaille N., Duval M., Tucci M., Lacroix J., Alfieri C.: Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. Transfusion, 2012;52:2653-2663
105. van den Bosch C. A.: Is endemic Burkitt's lymphoma an alliance between three infections and a tumor promoter? Lancet Oncol., 2004;5:738-746
106. Wagner H. J., Rooney C. M., Heslop H. E.: Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 2002;8:1-8
107. Wakiguchi H.: Overview of Epstein-Barr virus-associated diseases in Japan. Crit Rev. Oncol. Hematol., 2002;44:193-202
108. Wang D., Liebowitz D., Kieff E.: An EBV membrane protein expressed in immortalized lymphocytestransforms established rodent cells. Cell, 1985;43:831-840
109. Weiss L. M., Jaffe E. S., Liu X. F., Chen Y. Y., Shibata D., Medeiros L. J.: Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood, 1992;79:1789-1795
110. Weiss L. M., Strickler J. G., Warnke R. A., Purtilo D. T., Sklar J.: Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am. J. Pathol., 1987;129:86-91
111. Wekerle H., Hohlfeld R.: Molecular mimicry in multiple sclerosis. N. Engl. J. Med., 2003;349:185-186
112. Wensing B., Farrell P. J.: Regulation of cell growth and death by Epstein-Barr virus. Microbes Infect., 2000;2:77-84
113. Went P., Agostinelli C., Gallamini A., Piccaluga P. P., Ascani S., Sabattini E., Bacci F., Falini B., Motta T., Paulli M., Artusi T., Piccioli M., Zinzani P. L., Pileri S. A.: Marker expression in peripheral T cell lymphoma: A proposed clinical-pathologic prognostic score. J. Clin. Oncol., 2006;24:2472-2479
114. Wilson J. B., Bell J. L., Levine A. J.: Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J., 1996;15:3117-3126
115. Wright D. H.: What is Burkitt's lymphoma and when is it endemic? Blood, 1999;93:758
116. Young L. S.: Epstein-Barr Virus: General Features. In: Encyclopedia of Virology, eds.: Mahy B. W. J., van Regenmortel M. H. V., Academic Press, Oxford 2008, 148-157
117. Young L. S., Murray P. G.: Epstein-Barr virus and oncogenesis: from latent genes to tumors. Oncogene, 2003;22, 5108-5121
118. Young L. S., Rickinson A. B.: Epstein-Barr virus: 40 years on. Nat. Rev. Cancer, 2004;4:757-768
119. Yustein J. T., Dang C. V.: Biology and treatment of Burkitt's lymphoma. Curr. Opin. Hematol., 2007;14:375-381